Form 4: Denali Capital Acquisition Corp. Director Sells 500,000 Class B Ordinary Shares in Deal with Scilex Holding Company

Jiandong Xu, a director of Denali Capital Acquisition Corp., sold 500,000 Class B ordinary shares to Scilex Holding Company as part of a Sponsor Interest Purchase Agreement related to a merger.

Summary

• Jiandong Xu, a director of Denali Capital Acquisition Corp. (DECA), sold 500,000 Class B ordinary shares on August 30, 2024.
• The sale was made to Scilex Holding Company ('Scilex') as part of a Sponsor Interest Purchase Agreement ('SIPA').
• The consideration for the shares included $2,000,000 in cash and 300,000 shares of Scilex common stock.
• The cash consideration was paid on August 30, 2024, while the Scilex shares are contingent upon the effective time of the merger between Denali Merger Sub Inc. and Semnur Pharmaceuticals, Inc., a subsidiary of Scilex.
• Xu also indirectly owns 1,432,500 Class B ordinary shares through the Sponsor, where he is the manager and controlling member.

Sentiment

Score: 5

Explanation: Neutral sentiment as it reports a transaction related to a merger. The sale of shares by a director doesn't inherently indicate positive or negative sentiment without further context.

Future Outlook

The completion of the merger between Denali Merger Sub Inc. and Semnur Pharmaceuticals, Inc. is a key event that will trigger the issuance of Scilex shares to Jiandong Xu.

Industry Context

This transaction is related to a SPAC merger, a common structure in the current market. The sale of shares by a director in connection with a merger is not unusual, but the terms of the deal, including the consideration and contingencies, are specific to this situation.

Related Party Transactions

• The Sponsor Interest Purchase Agreement between Jiandong Xu and Scilex Holding Company is a related party transaction.

Stakeholder Impact

• Shareholders of Denali Capital Acquisition Corp. will be impacted by the merger with Semnur Pharmaceuticals, Inc.
• The transaction affects the ownership structure of Denali Capital Acquisition Corp.

Next Steps

• Completion of the merger between Denali Merger Sub Inc. and Semnur Pharmaceuticals, Inc.
• Issuance of 300,000 Scilex shares to Jiandong Xu upon the merger's effective time.

Key Dates